Sex differences in escape-avoidance response in mice after acute administration of raclopride, clozapine, and SCH 23390

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 2, 1998, Pages 489-497

  Monleón, Santiago ^a   Vinader Caerols, Concepción ^a   Parra, Andrés ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Active avoidance; Clozapine; Learning; Mice; Neuroleptics; Raclopride; SCH 23390; Sex differences

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; RACLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; ESCAPE BEHAVIOR; FEMALE; LEARNING; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; AVOIDANCE LEARNING; CLOZAPINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCAPE REACTION; FEMALE; MALE; MICE; RACLOPRIDE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SEX CHARACTERISTICS;

EID: 0032100583     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00009-4     Document Type: Article

References (67)

1. Aguilar M.A., Rodríguez-Arias M., Miñarro J., Simón V.M. Time course of the effects of haloperidol on agonistic behaviour in male mice. Psicothema. 6:1994;191-196.
2. Anisman H., Zacharko R.M. Stimulus change influences escape performance. Deficits induced by uncontrollable stress and by haloperidol Pharmacol. Biochem. Behav. 17:1982;263-269.
3. Arenas M.C., Parra A., Simón V.M. Gender differences in escape-avoidance behavior of mice after haloperidol administration. Pharmacol. Biochem. Behav. 44:1993;233-236.
4. Arenas M.C., Parra A., Simón V.M. Gender differences in the effects of haloperidol on avoidance conditioning in mice. Pharmacol. Biochem. Behav. 51:1995;601-609.
5. Arenas M.C., Parra A., Simón V.M. Effects of haloperidol on the acquisition of avoidance conditioning in ovariectomized mice. Med. Sci. Res. 23:1995;343-345.
6. Baptista T., Parada M., Hernández L. Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol. Biochem. Behav. 27:1987;399-405.
7. Blackburn J.R., Philips A.G. Blockade of acquisition of one-way conditioned avoidance responding by haloperidol and metoclopramide but not by thioridazine or clozapine. Implications for screening new antipsychotic drugs Psychopharmacology (Berlin). 98:1989;453-459.
8. A receptors by estradiol. A clue for CNS changes occurring at menopause Cell. Mol. Neurobiol. 16:1996;199-212.
9. Britton D.R., Curzon P., Yahiro L., Buckley M., Tufano M., Nadzan A. Evaluation of a stable CCK agonist (A68552) in C.A.R. in mice, rats, and primates. Comparison with typical and atypical antypsychotics Pharmacol. Biochem. Behav. 43:1992;369-376.
10. Brunello N., Masotto C., Steardo L., Markstein R., Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology. 13:1995;177-213.
11. Campbell A., Baldessarini R.J., Cremens M.C. Dose-catalepsy response to haloperidol in rat. Effects of strain and sex Neuropharmacology. 27:1988;1197-1199.
12. Carey R.J., Keney S. A delay onset of haloperidol effects on learned escape and avoidance behavior. Pharmacol. Biochem. Behav. 28:1987;203-208.
13. Carlton P.E. A primer of behavioral pharmacology. Concepts and principles in the behavioral analysis of drug action. 1983;W. H. Freeman & Company, New York.
14. Clark D., Carlsson A., Hjorth S., Engel J., Lindberg P. The effect of the enantiomers of 3-PPP on conditioned avoidance responding in the rat. Psychopharmacology (Berlin). 81:1983;14-17.
15. Dalton J.C.H., Vickers G.J., Roberts C.S. Increased self-administration of cocaine following haloperidol. Sex-dependent effects of the antiestrogen tamoxifen Pharmacol. Biochem. Behav. 25:1986;497-501.
16. 2-like' agonist, RU 24213. Br. J. Pharmacol. 113:1994;839-844.
17. Davidson A.B., Weidley E. Differential effects of neuroleptic and other psychotropic agents on acquisition of avoidance in rats. Life Sci. 18:1976;1279-1284.
18. Dawkins K. Gender differences in psychiatry. Epidemiology and drug response. CNS Drugs. 3:1995;393-407.
19. De la Cruz F., Pellis S.M., Pellis V.C. Sex differences in the effects of haloperidol, morphine, and their combination on colonic temperature in rats. Exp. Neurol. 96:1987;376-380.
20. Díaz-Véliz G., Soto V., Dussaubat N., Mora S. Influence of the estrous cycle, ovariectomy and estradiol replacement upon the acquisition of conditioned avoidance responses in rats. Physiol. Behav. 46:1989;397-401.
21. Díaz-Véliz G., Urresta F., Dussaubat N., Mora S. Effects of estradiol replacement in ovariectomized rats on conditioned avoidance responses and other behaviors. Physiol. Behav. 50:1991;61-65.
22. Díaz-Véliz G., Baeza R., Benavente F., Dussaubat N., Mora S. Influence of the estrous cycle and estradiol on the behavioral effects of amphetamine and apomorphine in rats. Pharmacol. Biochem. Behav. 49:1994;819-825.
23. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. Rev. Neurosci. 5:1994;27-41.
24. Farde L., Wiesel F.A., Jansson P., Uppfeldt G., Wahlen A., Sedvall G. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology (Berlin). 94:1988;1-7.
25. Farde L., Wiesel F.A., Nordström A.L., Sedvall G. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berlin). 99:1989;S28-S31.
26. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Arch. Gen. Psychiatry. 49:1992;538-544.
27. 1 receptors in the initiation of heroin self-administration in the rat. Psychopharmacology (Berlin). 114:1994;486-494.
28. Gleiter C.H., Gundert-Remy U. Gender differences in pharmacokinetics. Eur. J. Drug Metab. Pharmacokinet. 21:1996;123-128.
29. Häfner H., Behrens S., DeVry J., Gattaz W.F. An animal model for the effects of estradiol on dopamine-mediated behavior. Implications for sex differences in schizophrenia Psychiatr. Res. 38:1991;125-134.
30. Häfner H., Riecher-Rössler A., Heiden W., An Der, Maurer K., Fätkenheurer B., Löffler W. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychol. Med. 23:1993;925-940.
31. Halbreich U., Asnis G., Goldstein S., Nathan R.S., Zander K., Herne J.V. Sex differences in response to psychopharmacological interventions in humans. Psychopharmacol. Bull. 20:1984;526-530.
32. Hayashi T., Tadokoro S., Hashimoto H., Nakashima M. Enhancement of avoidance-suppressing effect after repeated administration of haloperidol and serum haloperidol in rats. Pharmacol. Biochem. Behav. 17:1982;131-136.
33. Herz A. Drugs and the conditioned avoidance response. Int. Rev. Neurobiol. 2:1960;229-277.
34. Hest A., Van, Haaren F., Van, Poll N.E., Van de Haloperidol, but not apomorphine, differentially affects low response rates of male and female Wistar rats. Pharmacol. Biochem. Behav. 29:1988;529-532.
35. Hyttel J. SCH 23390 - The first selective dopamine D-1 antagonist. Eur. J. Pharmacol. 91:1983;153-154.
36. Iorio L.C., Barnett A., Leitz F.H., Houser V.P., Korduba C.A. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther. 226:1983;462-468.
37. Jeste D., Lindamer L., Evans J., Lacro J. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol. Bull. 32:1996;243-251.
38. Lehr E. Testing antipsychotic drug effects with operant behavioral techniques. Hoffmeister F., Stille G. Psychotropic agents. Part I. Antipsychotics and antidepressants:1980;89-95 Springer Verlag, Berlin.
39. Levesque D., Di Paolo T. Dopamine receptor reappearance after irreversible receptor blockade. Effect of chronic estradiol treatment of ovariectomized rats Mol. Pharmacol. 39:1991;659-665.
40. Lynch M.R. Behavioral evidence for dopamine receptor subsentivity following chronic haloperidol. Neuropsychobiology. 24:1990;102-108.
41. Miller L.G., Jankovic J. Neurologic approach to drug-induced movement disorders. A study of 125 patients Southern Med. J. 83:1990;525-532.
42. Monleón S., Parra A. Sex differences in escape-avoidance behaviour in BALB/c mice after haloperidol administration. Med. Sci. Res. 25:1997;565-567.
43. Monleón S., Parra A. The higher the dose, the greater the sex differences in escape-avoidance response in mice after acute administration of haloperidol. Pharmacol. Biochem. Behav. 60:1998;279-284.
44. Nakajima S., Baker J. Effects of D2 dopamine receptor blockade with raclopride and food-reinforced operant behaviour. Psychopharmacology (Berlin). 98:1989;330-333.
45. Navarro J.F., Vera F., Puigcerver A., Martín-López M. Gender differences in catalepsy of mice after haloperidol administration. Med. Sci. Res. 21:1993;815-816.
46. Nielsen E.B., Hansen J.B., Gronvald F.C., Swedberg M.D.B., Scheideler M. NNC 19 1228 and NNC 22 0031, novel neuroleptics with a mesolimbic selective behavioral profile. Psychopharmacology (Berlin). 129:1997;168-178.
47. Ögren S.O., Archer T. Effects of typical and atypical antipsychotic drugs on two-way active avoidance. Relationship to DA receptor blocking profile. Psychopharmacology (Berlin). 114:1994;383-391.
48. Palermo-Neto J., Dorce V.A.C. Influences of estrogen and/or progesterone on some dopamine related behavior in rats. Gen. Pharmacol. 21:1990;83-87.
49. Petty F., Mott J., Sherman A.D. Potential locus and mechanism of blockade of conditioned avoidance responding by neuroleptics. Neuropharmacology. 23:1984;73-78.
50. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet. 4:1995;557-562.
51. Pickar D., Hsiao J.K. Clozapine treatment of schizophrenia. JAMA. 274:1995;981-983.
52. Rodríguez R. Effect of various psychotropic drugs on the performance of avoidance and escape behaviors in rats. Pharmacol. Biochem. Behav. 43:1992;1155-1159.
53. Rupniak N.M.J., Mann S., Hall M.D., Fleminger S., Kilpatrick G., Jenner P., Marsden C.D. Differential alterations in striatal acetylcholine function in rats during 12 months' continuous administration of haloperidol, sulpiride or clozapine. Clin. Neuropharmacol. 9:1986;282-292.
54. Salmi P., Samuelsson J., Ahlenius S. A new computer-assisted two-way avoidance conditioning equipment for rats. Behavioral and pharmacological validation J. Pharmacol. Methods. 32:1994;155-159.
55. Salokangas R.K.R. Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis. Schizophr. Res. 16:1995;7-16.
56. Sanger D.J. The effects of clozapine on shuttle-box avoidance responding in rats; Comparisons with haloperidol and chlordiazepoxide. Pharmacol. Biochem. Behav. 23:1985;231-236.
57. Seeman M.V. Interaction of sex, age, and neuroleptic dose. Comp. Psychiatry. 24:1983;125-128.
58. Seeman M.V. Current outcome in schizophrenia. Women vs men Acta Psychiatr. Scand. 73:1986;609-617.
59. Seeman M.V. Sex differences in the prediction of neuroleptic response. Gaebel W., Awad A.G. Prediction of neuroleptic treatment outcome in schizophrenia. Concepts and methods. 1994;51-64 Springer Verlag, New York.
60. Seeman M.V., Lang M. The role of estrogens in schizophrenia gender differences. Schizophr. Bull. 16:1990;185-194.
61. Szymanski S., Lieberman J., Alvir J., Mayerhoff D., Loebel A., Geisler S., Chakos M., Koreen A., Jody D., Kane J., Woerner M., Cooper T. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am. J. Psychiatry. 152:1995;698-703.
62. Szymanski S., Lieberman J., Pollack S., Kane J., Safferman A., Munne R., Umbricht D., Woerner M., Masiar S., Kroning M. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol. Psychiatry. 39:1996;249-254.
63. Wadenberg M.L., Ahlenius S. Effects of raclopride and haloperidol on spontaneous motor activity and on conditioned avoidance behavior in rats. A comparison of potency, efficacy and time-course action. Drug Res. 41:1991;692-695.
64. Wadenberg M.L., Salmi P., Jiménez P., Svenson T., Ahlenius S. Enhancement of antipsychotic like properties of the dopamine D2 receptor antagonist, raclopride, by the addition al treatment with the 5HT2 receptor blocking agent, ritanserin, in the rat. Eur. Neuropsychopharmacol. 6:1996;305-310.
65. Weiner I., Feldon J., Katz Y. Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacol. Biochem. Behav. 26:1987;241-246.
66. White I.M., Ciancone M.T., Haracz J.L., Rebec G.V. A lever-release version of the conditioned avoidance response paradigm. Effects of haloperidol, clozapine, sulpiride, and BMY-14802 Pharmacol. Biochem. Behav. 41:1992;29-35.
67. Yonkers K.A., Kando J.C., Cole J.O., Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am. J. Psychiatry. 149:1992;587-595.